MR. KEVIN M O'HARA PA
Prescription History 1235463522
Physician Assistant - Medical in New Haven, CT
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MR. KEVIN M O'HARA PA, an active Medical specialist practicing in New Haven, CT. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 186 documented patient claims. Among these therapy options, the most frequently utilized medication is Acyclovir, which accounts for 71 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2024)Rx (2024) | Avg Cost per FillCost / Fill | Vs. Other CT PrescribersVs. CT Avg |
|---|---|---|---|
| Acyclovir | 71 | $9.75▼ below CT avg | ▲ More than typical |
About Acyclovir: Acyclovir is used to treat infections caused by certain types of viruses. Show more ▾ It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir is an antiviral drug. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections. A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. In 2024, this provider wrote 71 Medicare prescriptions for Acyclovir, about 2.2 times the volume of the typical Connecticut prescriber of this medication (33). Medicare paid an average of $9.75 per fill, versus $17.90 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average CT prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CT average for this medication. 89 30-Day Fills standardized to 30-day supplies 2,670 Days of Medication total across all patients in 2024 | |||
| CalquenceAcalabrutinib Maleate | 44 | $15,862.03 | ▲ More than typical |
About Calquence: This medication is used to treat certain types of cancer (such as mantle cell lymphoma, small lymphocytic lymphoma - SLL, chronic lymphocytic leukemia - CLL). Show more ▾ Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors. Inhibits Bruton’s tyrosine kinase; has antineoplastic activity. In 2024, this provider wrote 44 Medicare prescriptions for Calquence, about 1.6 times the volume of the typical Connecticut prescriber of this medication (26.8). Medicare paid an average of $15,862.03 per fill, versus $14,138.54 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average CT prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 52 30-Day Fills standardized to 30-day supplies 1,560 Days of Medication total across all patients in 2024 | |||
| BrukinsaZanubrutinib | 26 | $11,209.66▼ below CT avg | ≈ Typical |
About Brukinsa: This medication is used to treat certain cancers (mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia, chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma). Show more ▾ Zanubrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. A Bruton tyrosine kinase (BTK) inhibitor for treatment of Waldenstrom macroglobulinemia. In 2024, this provider wrote 26 Medicare prescriptions for Brukinsa, about the same volume as the typical Connecticut prescriber of this medication (25.8). Medicare paid an average of $11,209.66 per fill, versus $13,181.98 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average CT prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CT average for this medication. 26 30-Day Fills standardized to 30-day supplies 780 Days of Medication total across all patients in 2024 | |||
| Entecavir | 18 | $288.51 | ≈ Typical |
About Entecavir: See also Warning section. Show more ▾ Entecavir is used to treat long-term hepatitis B infection. Hepatitis B is an infection of the liver caused by the hepatitis B virus. Long-term infection can cause liver damage, rarely liver cancer, and liver failure. Entecavir helps to decrease the amount of hepatitis B virus in your body. It is unknown if this medication lowers your chance of getting liver cancer or liver damage. Entecavir is an antiviral that belongs to a class of drugs known as hepatitis B virus nucleoside reverse transcriptase inhibitors. Entecavir is not a cure for hepatitis B. It does not prevent the spread of the virus to others through sexual contact or blood/body fluid contamination (such as sharing used needles). In 2024, this provider wrote 18 Medicare prescriptions for Entecavir, about 81% of the volume of the typical Connecticut prescriber of this medication (22.2). Medicare paid an average of $288.51 per fill, versus $137.93 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average CT prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 18 30-Day Fills standardized to 30-day supplies 540 Days of Medication total across all patients in 2024 | |||
| Prednisone | 15 | $3.84▼ below CT avg | ▼ Less than typical |
About Prednisone: Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Show more ▾ Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions. A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. In 2024, this provider wrote 15 Medicare prescriptions for Prednisone, about a third of the volume of the typical Connecticut prescriber of this medication (48.7). Medicare paid an average of $3.84 per fill, versus $4.39 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average CT prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CT average for this medication. 15 30-Day Fills standardized to 30-day supplies 145 Days of Medication total across all patients in 2024 | |||
| Lenalidomide | 12 | $12,520.73▼ below CT avg | ▼ Less than typical |
About Lenalidomide: Lenalidomide is used to treat various types of cancers. Show more ▾ It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication. A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA. In 2024, this provider wrote 12 Medicare prescriptions for Lenalidomide, about a third of the volume of the typical Connecticut prescriber of this medication (29.5). Medicare paid an average of $12,520.73 per fill, versus $13,071.90 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average CT prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CT average for this medication. 12 30-Day Fills standardized to 30-day supplies 328 Days of Medication total across all patients in 2024 | |||
About this data. The prescription history for MR. KEVIN M O'HARA PA is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2024, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Medical prescribing approach at this New Haven, CT practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average among CT prescribers of the same medication and form, shown only when at least five prescribers contribute. Always confirm current medications and costs directly with the provider and your plan.
About the medication summaries. Drug use descriptions come from the CMS Medicare Part D Drug Spending Dashboard (2024), and substance definitions from Medical Subject Headings (MeSH) 2026, U.S. National Library of Medicine. They are summaries that do not contain all possible information about a medication and are not individual medical advice. Ask a health care professional about any medication and your specific health needs.
